- Home
- AIRT vs ECOR Comparison
AIRT vs ECOR Comparison
Compare AIRT & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRT
- ECOR
- Stock Information
- Founded
- AIRT 1980
- ECOR 2005
- Country
- AIRT United States
- ECOR United States
- Employees
- AIRT N/A
- ECOR N/A
- Industry
- AIRT Air Freight/Delivery Services
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AIRT Consumer Discretionary
- ECOR Health Care
- Exchange
- AIRT Nasdaq
- ECOR Nasdaq
- Market Cap
- AIRT 53.2M
- ECOR 50.1M
- IPO Year
- AIRT N/A
- ECOR 2018
- Fundamental
- Price
- AIRT $21.13
- ECOR $5.36
- Analyst Decision
- AIRT
- ECOR Strong Buy
- Analyst Count
- AIRT 0
- ECOR 2
- Target Price
- AIRT N/A
- ECOR $25.50
- AVG Volume (30 Days)
- AIRT 2.7K
- ECOR 67.6K
- Earning Date
- AIRT 06-27-2025
- ECOR 08-06-2025
- Dividend Yield
- AIRT N/A
- ECOR N/A
- EPS Growth
- AIRT N/A
- ECOR N/A
- EPS
- AIRT N/A
- ECOR N/A
- Revenue
- AIRT $291,850,000.00
- ECOR $26,458,000.00
- Revenue This Year
- AIRT N/A
- ECOR $23.21
- Revenue Next Year
- AIRT N/A
- ECOR $44.10
- P/E Ratio
- AIRT N/A
- ECOR N/A
- Revenue Growth
- AIRT 1.75
- ECOR 41.54
- 52 Week Low
- AIRT $14.56
- ECOR $4.47
- 52 Week High
- AIRT $30.60
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- AIRT 54.46
- ECOR 49.17
- Support Level
- AIRT $18.86
- ECOR $5.13
- Resistance Level
- AIRT $22.50
- ECOR $5.69
- Average True Range (ATR)
- AIRT 1.12
- ECOR 0.39
- MACD
- AIRT -0.05
- ECOR 0.04
- Stochastic Oscillator
- AIRT 47.07
- ECOR 41.15
About AIRT Air T Inc.
Air T Inc together with its subsidiaries provides air freight service to the express delivery industry. The company's operating segments include Overnight air cargo, Ground equipment sales, Commercial jet engines, and parts, Corporate, and Others. The company generates maximum revenue from the Commercial Jet Engines and Parts segment.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.